Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
Thailand has been experiencing significant growth in its pharmaceuticals market in recent years.
Customer preferences: Thai consumers have been increasingly demanding high-quality healthcare services, including pharmaceutical products. They prefer products that are affordable, effective, and have minimal side effects. Moreover, the aging population in Thailand has led to a rise in chronic diseases, which has further increased the demand for pharmaceutical products.
Trends in the market: One of the major trends in the Thai pharmaceuticals market is the shift towards generic drugs. This is due to the government's policy to promote the use of affordable generic drugs and reduce healthcare costs. Another trend is the increasing investment in research and development by pharmaceutical companies to develop innovative drugs and treatments. Additionally, there has been a rise in the use of digital technologies in healthcare, such as telemedicine and e-pharmacies, which has made healthcare services more accessible and convenient for consumers.
Local special circumstances: The Thai government has implemented several policies to promote the growth of the pharmaceuticals market, such as the establishment of the Thailand Center of Excellence for Life Sciences (TCELS) to support research and development in the industry. Moreover, the government has introduced tax incentives to attract foreign pharmaceutical companies to invest in the country.
Underlying macroeconomic factors: Thailand's strong economic growth and increasing healthcare expenditure have contributed to the growth of the pharmaceuticals market. Additionally, the country's strategic location and well-developed infrastructure have made it an attractive destination for pharmaceutical companies to invest in.In conclusion, Thailand's pharmaceuticals market is experiencing significant growth due to the increasing demand for high-quality healthcare services, the shift towards generic drugs, and the government's policies to promote the industry. The use of digital technologies and the country's favorable macroeconomic conditions are also contributing to the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)